Health authorities in Brazil have authorised the use of new pharmaceutical treatments targeting three significant medical conditions: type 1 diabetes, advanced breast cancer and hereditary angioedema. The approvals were granted by Brazil’s National Health Surveillance Agency, marking an important regulatory step in expanding therapeutic options for patients affected by chronic and complex diseases in the country.
One of the newly authorised therapies is teplizumab, marketed internationally as Tzield®. The treatment is designed to delay the progression of type 1 diabetes in individuals who are already at a pre-symptomatic stage of the disease. According to regulatory information published in Brazil, the therapy can be used in adults and children aged eight years and older who have reached stage 2 of the condition but have not yet developed full clinical symptoms.
Type 1 diabetes is recognised as a long-term autoimmune disorder in which the immune system mistakenly attacks insulin-producing beta cells in the pancreas. The condition frequently develops during childhood or adolescence and requires lifelong management. Scientific literature, including studies published in journals such as The New England Journal of Medicine, has shown that immune-modulating therapies like teplizumab may slow the destruction of pancreatic cells, potentially postponing the need for insulin therapy in high-risk patients.
Brazil’s regulator also authorised the use of Datroway®, a medicine intended for adults with advanced breast cancer that cannot be surgically removed or has spread to other parts of the body. The treatment is indicated for patients whose tumours are hormone-receptor positive and HER2-negative, and who have previously undergone endocrine therapy as well as at least one chemotherapy regimen for advanced disease. Breast cancer remains one of the most prevalent malignancies worldwide, and the availability of new targeted treatments is considered an important development for patients whose disease no longer responds to earlier lines of therapy.
In addition, the agency approved Andembry® (garadacimab) for the prevention of hereditary angioedema, a rare genetic condition characterised by sudden episodes of swelling that can affect the skin, gastrointestinal tract and airways. These attacks may occur unpredictably and can cause severe pain and, in some cases, life-threatening complications if the airway becomes obstructed. Research in immunology and rare disease medicine has highlighted the importance of preventive therapies in reducing the frequency and severity of these episodes.
The introduction of these medicines in Brazil reflects a broader global trend toward precision medicine and targeted therapies for complex diseases. By expanding access to treatments that address different biological mechanisms—autoimmune responses, tumour growth pathways and inflammatory processes—health authorities aim to improve disease management and patient outcomes across several therapeutic areas.
Medical specialists emphasise that regulatory approval represents only the first step in ensuring patient access. Clinical guidance, physician training and healthcare system integration will play key roles in determining how widely these therapies become available within Brazil’s healthcare network. Nevertheless, the decision is widely viewed as a significant advancement for patients living with these challenging conditions.